Trials / Completed
CompletedNCT00060489
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SEROQUEL (quetiapine fumarate) Tablets |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2003-09-01
- Completion
- 2003-09-01
- First posted
- 2003-05-08
- Last updated
- 2011-01-26
Locations
27 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00060489. Inclusion in this directory is not an endorsement.